Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology.
Employees: 51-200
Total raised: $15M
Founded date: 2014
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.11.2022 | - | $15M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 13.03.2024 | NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescript... | - | globenewsw... |
| 05.03.2024 | Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approv... | - | globenewsw... |
| 29.11.2022 | Eyenovia Announces $15 Million Credit Facility with Avenue V... | - | globenewsw... |
| 29.11.2022 | Eyenovia Secures $15M for Ophthalmic Drug Delivery Technolog... | What You Should Know: Eyenovia is developing a pipeline of advanced therapeutics based on its propri... | hitconsult... |
| 07.06.2022 | Immatics and Editas partner on gene editing and T cell... | Two companies deeply involved in gene editing and T-cells are coming together in a new deal. ... | endpts.com... |
| 25.10.2021 | EYENOVIA, INC. : Results of Operations and Financial Conditi... | Item 2.02 Results of Operations and Financial Condition. Eyenovia, Inc. (the "Company") ex... | marketscre... |